Alnylam Pharmaceuticals (ALNY) EBT Growth (1y) (2010 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) EBT Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 76.53% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -522.15% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 8.48% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 0.60% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 88.92% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 6.23% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 530.43% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -82.20% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 96.45% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -118.96% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 530.43% |
| Mar 31, 2026 | 9,460.35% |
| Dec 31, 2025 | 144.47% |
| Sep 30, 2025 | 358.20% |
| Jun 30, 2025 | -269.92% |
| Mar 31, 2025 | 96.28% |
| Dec 31, 2024 | -40.87% |
| Sep 30, 2024 | -172.09% |
| Jun 30, 2024 | 95.93% |
| Mar 31, 2024 | 63.11% |
| Dec 31, 2023 | 33.49% |
| Sep 30, 2023 | 137.13% |
| Jun 30, 2023 | 0.17% |
| Mar 31, 2023 | 27.99% |
| Dec 31, 2022 | 20.47% |
| Sep 30, 2022 | -98.76% |
| Jun 30, 2022 | -45.85% |
| Mar 31, 2022 | -20.11% |
| Dec 31, 2021 | -6.86% |
| Sep 30, 2021 | 19.10% |